[A comparison of systemic radiotherapy, chemotherapy or local radiotherapy in the treatment of extensive small-cell bronchial carcinoma. Results of a randomized series].
Between 1982 and 1987 we carried out a prospective randomized study to compare the effectiveness of high-dose half-body irradiation (HBI) (A), intensive combined chemotherapy (B), and local or locoregional radiotherapy (C) in the therapy of extended small cell lung carcinoma (SCLC). 99 patients with a histologically proved SCLC were assigned to the three therapeutic groups of series: A = 31 patients, B = 37 patients, C = 31 patients. The median survival period showed a statistically significant advantage (p less than 0.01) for the chemotherapy group (B = 46 weeks) versus the two radiotherapy groups (A = 19 weeks, C = 23 weeks). The survival after half a year, one year, and two years also gave a clear advantage for the chemotherapy group. No difference was found between the radiotherapy groups A and C. The high-dose HBI gave no improvement of the sad therapeutic situation for the extended SCLC.
Hüttner
J
J
Zentralinstitut für Krebsforschung, Robert-Rössle-Institut, Akademie der Wissenschaften der DDR, Berlin.
Grunau
H
H
Dallüge
K H
KH
Wiener
N
N
Quadt
C
C
Merkle
K
K
Lessel
A
A
Rotte
K H
KH
Schmitz
B
B
Kleinau
H
H
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002283:Carcinoma, Bronchogenic / Q000401:mortality / Q000628:therapy*; D018288:Carcinoma, Small Cell / Q000401:mortality / Q000628:therapy*; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000401:mortality / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D011878:Radiotherapy / Q000379:methods*; D016032:Randomized Controlled Trials as Topic; D015996:Survival Rate
Vergleich zwischen systemischer Strahlentherapie, Chemotherapie oder lokaler Strahlentherapie bei der Behandlung des ausgedehnten kleinzelligen Bronchialkarzinoms. Ergebnisse einer randomisierten Serie.